Inhibrx Biosciences Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on Inhibrx Biosciences's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 14.5% |
| Return on equity | 784.2% |
| Net Margin | 101,974.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Inhibrx Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | 1,720 | 114 | 0 |
| 31 Mar 24 | 2 | -185 | 28 | 0 |
| 31 Dec 23 | 2 | -155 | 24 | 0 |
| 31 Dec 22 | 1 | -115 | 15 | 0 |
Quality Earnings: INBX has a large one-off gain of $2.0B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: INBX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if INBX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare INBX's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: INBX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: INBX's Return on Equity (784.2%) is considered outstanding.